Results of Operations and Financial

X4 Pharmaceuticals, Inc. (the "Company") is currently in the process of finalizing its financial results for the fiscal year ended December 31, 2019. Based on information currently available as of the date of this Current Report, management estimates the Companys cash and cash equivalents as of December 31, 2019 to be approximately $130 million. The Companys actual cash and cash equivalents as of December 31, 2019 may differ from these preliminary estimates due to the completion of the Companys closing and auditing procedures with respect to the fiscal year ended December 31, 2019, final adjustments and other developments that may arise between now and the time the financial results for the fiscal year are finalized.

The information furnished under this Item 2.02 shall not be consider ed filed under the Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended (the Securities Act), or under the Exchange Act unless the Company expressly sets forth in such future filing that such information is to be considered filed or incorporated by reference therein.

Item 7.01 Regulation FD Disclosure.

On January 10, 2020, the Company updated its corporate presentation, which is available on the Investors tab of the Companys website under Events & Presentations. The presentation will be used in meetings with investors at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California beginning on January 12, 2020 as well as future meetings from time to time.

Item 8.01 Other Events.

An excerpt of the presentation slides from the corporate presentation are attached hereto as Exhibit 99.1 to this Current Report. The full corporate presentation is also available on the Investors tab of the Companys website under Events & Presentations.

Cautionary Note on Forward-looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Companys expectations and assumptions as of the date of this Current Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this Current Report include statements about the Companys estimated cash and cash equivalents as of December 31, 2019. Other factors that may cause the Companys actual results to differ from those expressed or implied in the forward-looking statements in this Current Report are discussed in the Companys filings with the U.S. Securities and Exchange Commission, including the Risk Factors sections contained therein. Except as required by law, the Company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Description

99.1

Excerpt from Corporate Presentation dated January 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

X4 PHARMACEUTICALS, INC.

Date: January 10, 2020

By:

/s/ Adam S. Mostafa

Adam Mostafa

Chief Financial Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

Departure of Directors or Certain - March 20, 2020
Entry into a Material Definitive - March 17, 2020
Securities to be offered to employees in employee benefit plans - March 13, 2020
Arsanis, Inc. Just Filed Its Annual Report: Net Loss per Share— ... - March 12, 2020
Arsanis: X4 Pharmaceuticals Provides Corporate Update And Reports Fourth Quarter And Full Year 2019 Financial Results - March 12, 2020

Auto Refresh

Feedback